CANbridge Reports P-I/II Study Results of CAN008 for Glioblastoma Multiforme
Shots:
- The company reported the long-term follow-up data from the P-I/II study of CAN008 (asunercept) + temozolomide/radiotherapy (TMZ/RT) in newly diagnosed glioblastoma multiforme
- The results showed an overall survival rate of the high-dose CAN008 group was 83% @2yrs. and 67% at 3/4/5yrs. over overall survival rate in the institutional GBM database of 34.3% @2yr.; 19.5% @3yr.; 16.1% @4yr. and 8.2% @5yr., the high-dose CAN008 cohort also showed m-PFS of 17.95mos. over 6.9mos. on TMZ/RT, 67% were alive after 5yrs. Interim results are expected in mid-2023
- A positive response to treatment with CAN008 was linked to high tumor mutation burden & DNAH family gene mutation. The results will be presented at ESMO 2023
Ref: Businesswire | Image: CANbridge
Related News:- CANbridge Reports NMPA Acceptance of NDA for AN108 to Treat Alagille Syndrome
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
